Life ScienceCompany
XBiotech - Novel Antibody Bermekimab Ownership
Who owns XBiotech - Novel Antibody Bermekimab?
XBiotech - Novel Antibody Bermekimab is owned by Janssen Pharmaceuticals. It was acquired on December 7, 2019.
XBiotech - Novel Antibody Bermekimab Business Overview
Where is XBiotech - Novel Antibody Bermekimab headquartered?
XBiotech - Novel Antibody Bermekimab is headquartered in Austin, Texas.
What sector is XBiotech - Novel Antibody Bermekimab in?
XBiotech - Novel Antibody Bermekimab is a life science company.
Life Science M&A Summary in 2019
Out of 60 sectors in the Mergr database, life science ranked 9 in number of deals in 2019. The largest life science acquisition in 2019 was Celgene - which was acquired by Bristol-Myers Squibb for $74.0B.
Join Mergr to view all 251 acquisitions of life science companies in 2019, including 44 acquisitions by private equity firms, and 207 by strategics.